Koers Ampliphi Biosciences Corp Nyse
Aandelen
APHB
US03211P2020
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 4,54 mln. 4,24 mln. | Omzet 2025 * | 2,75 mln. 2,57 mln. | Marktkapitalisatie | 99,43 mln. 92,82 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -72 mln. -67,22 mln. | Nettowinst (verlies) 2025 * | -67 mln. -62,55 mln. | EV/omzet 2024 * | 21,9 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 36,2 x |
K/w-verhouding 2024 * |
-1,44
x | K/w-verhouding 2025 * |
-2,12
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 29,72% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Deborah Birx
CEO | Chief Executive Officer | 68 | 11-07-23 |
Richard Rychlik
DFI | Director of Finance/CFO | 68 | 05-09-23 |
Mina Pastagia
CTO | Chief Tech/Sci/R&D Officer | - | 26-10-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 64 | 12-02-20 | |
Joseph Patti
BRD | Director/Board Member | 60 | 09-05-19 |
Jules Haimovitz
BRD | Director/Board Member | 73 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,65% | 39,36 mld. | |
-8,62% | 38,52 mld. | |
+26,95% | 30,74 mld. | |
+10,74% | 25,92 mld. | |
-13,50% | 26,03 mld. | |
+44,87% | 14,13 mld. | |
+34,36% | 12,73 mld. | |
-7,14% | 11,29 mld. | |
-12,61% | 10,64 mld. |